Enzo BioChem posts $10.3M quarterly loss
Enzo BioChem Inc., Manhattan
Biotechnology developer; parent company of Enzo Clinical Labs, of Farmingdale
Second Quarter: Ended Jan. 31
Net revenue: Rose to $23.2 million from $21 million in the year-ago quarter.
Net income: Loss of $10.3 million, compared to a loss of $7.7 million in the same quarter last year.
Company statement: "The fiscal second quarter reflected another quarter of improved operating results, excluding unusually high proxy-related costs and a one-time payment to a former officer to settle litigation and the related legal costs," Barry Weiner, the company president, said in a statement. "Margin improvement reflected a more favorable mix of products at Enzo Life Sciences and a higher percentage of esoteric testing at Enzo Clinical Labs."
Sarra Sounds Off, Season 3, Ep 3: Top football teams in action, fantasy update and plays of the week Gregg Sarra sounds off on the Northport and Half Hollow Hills East matchup, plus Tess Ferguson has an update on the high school fantasy football standings and Jared Vailuzzi has the plays of the week.
Sarra Sounds Off, Season 3, Ep 3: Top football teams in action, fantasy update and plays of the week Gregg Sarra sounds off on the Northport and Half Hollow Hills East matchup, plus Tess Ferguson has an update on the high school fantasy football standings and Jared Vailuzzi has the plays of the week.
